Microenvironmental Determinants of Breast Cancer Metastasis: Focus on the Crucial Interplay Between Estrogen and Insulin/Insulin-Like Growth Factor Signaling.
GPER
breast cancer
estrogen receptor
insulin/IGF signaling
metastasis
targeted therapies
tumor microenvionment
Journal
Frontiers in cell and developmental biology
ISSN: 2296-634X
Titre abrégé: Front Cell Dev Biol
Pays: Switzerland
ID NLM: 101630250
Informations de publication
Date de publication:
2020
2020
Historique:
received:
20
09
2020
accepted:
09
11
2020
entrez:
28
12
2020
pubmed:
29
12
2020
medline:
29
12
2020
Statut:
epublish
Résumé
The development and progression of the great majority of breast cancers (BCs) are mainly dependent on the biological action elicited by estrogens through the classical estrogen receptor (ER), as well as the alternate receptor named G-protein-coupled estrogen receptor (GPER). In addition to estrogens, other hormones and growth factors, including the insulin and insulin-like growth factor system (IIGFs), play a role in BC. IIGFs cooperates with estrogen signaling to generate a multilevel cross-communication that ultimately facilitates the transition toward aggressive and life-threatening BC phenotypes. In this regard, the majority of BC deaths are correlated with the formation of metastatic lesions at distant sites. A thorough scrutiny of the biological and biochemical events orchestrating metastasis formation and dissemination has shown that virtually all cell types within the tumor microenvironment work closely with BC cells to seed cancerous units at distant sites. By establishing an intricate scheme of paracrine interactions that lead to the expression of genes involved in metastasis initiation, progression, and virulence, the cross-talk between BC cells and the surrounding microenvironmental components does dictate tumor fate and patients' prognosis. Following (i) a description of the main microenvironmental events prompting BC metastases and (ii) a concise overview of estrogen and the IIGFs signaling and their major regulatory functions in BC, here we provide a comprehensive analysis of the most recent findings on the role of these transduction pathways toward metastatic dissemination. In particular, we focused our attention on the main microenvironmental targets of the estrogen-IIGFs interplay, and we recapitulated relevant molecular nodes that orientate shared biological responses fostering the metastatic program. On the basis of available studies, we propose that a functional cross-talk between estrogens and IIGFs, by affecting the BC microenvironment, may contribute to the metastatic process and may be regarded as a novel target for combination therapies aimed at preventing the metastatic evolution.
Identifiants
pubmed: 33364239
doi: 10.3389/fcell.2020.608412
pmc: PMC7753049
doi:
Types de publication
Journal Article
Review
Langues
eng
Pagination
608412Informations de copyright
Copyright © 2020 Vella, De Francesco, Lappano, Muoio, Manzella, Maggiolini and Belfiore.
Déclaration de conflit d'intérêts
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Références
Cell. 2014 Aug 28;158(5):1110-1122
pubmed: 25171411
ACS Appl Mater Interfaces. 2019 Oct 30;11(43):39545-39559
pubmed: 31617997
Mutat Res Rev Mutat Res. 2017 Apr - Jun;772:105-122
pubmed: 28528684
Breast Cancer Res Treat. 2015 Sep;153(2):323-35
pubmed: 26285644
Mol Endocrinol. 2003 Mar;17(3):309-17
pubmed: 12554774
Ann Oncol. 2007 Jun;18 Suppl 6:vi81-5
pubmed: 17591841
Int J Biol Sci. 2018 Nov 13;14(14):2083-2093
pubmed: 30585271
Curr Stem Cell Rep. 2018;4(1):81-94
pubmed: 29600163
Endocrinology. 2012 May;153(5):2152-63
pubmed: 22355074
J Steroid Biochem Mol Biol. 1998 Aug;66(4):203-10
pubmed: 9744517
Cell. 2008 May 16;133(4):704-15
pubmed: 18485877
Cancer Sci. 2020 Jan;111(1):47-58
pubmed: 31710162
Nat Commun. 2013;4:1821
pubmed: 23652009
Tumour Biol. 2016 Sep;37(9):11711-11721
pubmed: 27444280
Mol Endocrinol. 2002 Jan;16(1):116-27
pubmed: 11773443
Mol Cell Biol. 2004 Sep;24(17):7643-53
pubmed: 15314172
Front Endocrinol (Lausanne). 2020 Feb 20;11:58
pubmed: 32153503
Mol Endocrinol. 2005 Apr;19(4):833-42
pubmed: 15695368
Proc Natl Acad Sci U S A. 2014 Jan 21;111(3):984-9
pubmed: 24395782
J Steroid Biochem Mol Biol. 2018 Feb;176:49-56
pubmed: 28249728
Mol Med Rep. 2015 Jul;12(1):851-64
pubmed: 25824321
Mol Endocrinol. 2000 Oct;14(10):1649-60
pubmed: 11043579
Breast Cancer Res. 2017 Jun 19;19(1):70
pubmed: 28629450
Oncogene. 2017 Feb 9;36(6):840-849
pubmed: 27669436
Proc Natl Acad Sci U S A. 2010 Dec 14;107(50):21737-42
pubmed: 21098263
J Amino Acids. 2011;2011:812540
pubmed: 22312471
Clin Cancer Res. 2019 Dec 1;25(23):7229-7242
pubmed: 31515454
Matrix Biol. 2015 Apr;43:42-60
pubmed: 25728938
J Exp Clin Cancer Res. 2019 Aug 1;38(1):335
pubmed: 31370872
Cancer Res. 2015 Nov 15;75(22):4681-7
pubmed: 26471358
Clin Cancer Res. 2011 Apr 15;17(8):2314-27
pubmed: 21177763
Endocr Rev. 2017 Oct 1;38(5):379-431
pubmed: 28973479
Mol Cell Endocrinol. 2012 Sep 25;361(1-2):191-201
pubmed: 22580007
Int J Mol Sci. 2020 Apr 20;21(8):
pubmed: 32326116
Lancet. 1993 Jul 17;342(8864):148-9
pubmed: 8101258
Oncogene. 2019 Oct;38(43):6913-6925
pubmed: 31406251
Cancers (Basel). 2019 Mar 23;11(3):
pubmed: 30909585
Breast Cancer Res. 2015 Aug 19;17:112
pubmed: 26286584
Endocr Relat Cancer. 2016 Sep;23(9):747-58
pubmed: 27435064
Cell Signal. 2012 Aug;24(8):1515-21
pubmed: 22481093
Breast Cancer Res. 2013 May 12;15(3):R39
pubmed: 23663564
Oncotarget. 2017 Jun 27;8(26):43248-43270
pubmed: 28591735
Endocr Relat Cancer. 2010 Apr 21;17(2):373-82
pubmed: 20410173
Endocr Relat Cancer. 2011 Jul 04;18(4):R125-47
pubmed: 21606157
Nat Genet. 2003 Jan;33(1):49-54
pubmed: 12469122
Cells. 2019 Mar 07;8(3):
pubmed: 30866584
Cell. 2010 Apr 2;141(1):52-67
pubmed: 20371345
Breast. 2016 Dec;30:156-171
pubmed: 27750106
Am J Physiol Endocrinol Metab. 2014 Aug 1;307(3):E289-304
pubmed: 24918199
Appl Immunohistochem Mol Morphol. 2011 May;19(3):218-25
pubmed: 21217522
Biochem J. 2018 May 9;475(9):1611-1634
pubmed: 29743249
Cancer Res. 2008 Dec 15;68(24):10238-46
pubmed: 19074892
Oncogene. 2016 Oct 20;35(42):5515-5526
pubmed: 27086926
Mol Endocrinol. 2003 Apr;17(4):628-42
pubmed: 12554776
Oncotarget. 2016 Jan 12;7(2):1262-75
pubmed: 26556856
Int J Cancer. 2002 Jan 20;97(3):306-12
pubmed: 11774281
Cells. 2019 Sep 01;8(9):
pubmed: 31480557
Arch Physiol Biochem. 2008 Feb;114(1):23-37
pubmed: 18465356
Methods Mol Biol. 2019;1944:203-220
pubmed: 30840245
Nat Rev Cancer. 2003 Jun;3(6):453-8
pubmed: 12778135
Toxicol Appl Pharmacol. 2019 Feb 1;364:77-82
pubmed: 30578886
Mol Endocrinol. 1999 Feb;13(2):307-19
pubmed: 9973260
PLoS One. 2016 Mar 18;11(3):e0150564
pubmed: 26991655
Biochimie. 1999 Apr;81(4):403-7
pubmed: 10401676
Clin Cancer Res. 2016 Feb 1;22(3):609-20
pubmed: 26420858
Int J Mol Sci. 2018 Feb 19;19(2):
pubmed: 29463044
J Steroid Biochem Mol Biol. 2018 Feb;176:4-15
pubmed: 28347854
Breast Cancer Res Treat. 2011 Jul;128(2):457-66
pubmed: 21607586
Front Biosci (Elite Ed). 2012 Jan 01;4:453-61
pubmed: 22201885
J Biol Chem. 2000 Jun 16;275(24):18447-53
pubmed: 10749889
Int J Mol Sci. 2016 Aug 19;17(8):
pubmed: 27548161
Cancer Res. 1997 Jul 1;57(13):2606-10
pubmed: 9205064
Endocr Rev. 2009 Oct;30(6):586-623
pubmed: 19752219
J Cancer Res Clin Oncol. 2014 May;140(5):713-23
pubmed: 24553912
Mol Cell Biol. 2007 Apr;27(8):3165-75
pubmed: 17296734
Cancer Cell. 2012 Mar 20;21(3):309-22
pubmed: 22439926
Oncotarget. 2017 Jul 18;8(29):46728-46744
pubmed: 28596490
Oncol Rep. 2015 Apr;33(4):1929-37
pubmed: 25647524
Cancer Treat Rev. 2018 Feb;63:79-95
pubmed: 29253837
Sci Rep. 2016 Dec 20;6:39541
pubmed: 27996037
Oncotarget. 2017 Dec 28;9(12):10375-10387
pubmed: 29535813
Oncogene. 2012 Apr 5;31(14):1757-70
pubmed: 21860410
Medicine (Baltimore). 2016 Dec;95(49):e5602
pubmed: 27930583
J Hematol Oncol. 2017 Apr 17;10(1):89
pubmed: 28412963
Sci Rep. 2018 Nov 26;8(1):17361
pubmed: 30478273
J Exp Clin Cancer Res. 2020 Aug 10;39(1):153
pubmed: 32778144
Cancer Res. 2012 Aug 15;72(16):4238-49
pubmed: 22738911
Endocr Relat Cancer. 2011 Nov 14;18(6):699-709
pubmed: 21946410
PLoS One. 2013 Dec 04;8(12):e80933
pubmed: 24324647
Am Soc Clin Oncol Educ Book. 2013;:46-51
pubmed: 23714453
J Clin Invest. 2015 May;125(5):2123-35
pubmed: 25893606
Int J Mol Sci. 2019 Mar 20;20(6):
pubmed: 30897853
J Cell Sci. 2010 Oct 15;123(Pt 20):3558-65
pubmed: 20930144
Plast Reconstr Surg. 2015 Jul;136(1):76-84
pubmed: 26111315
Clin Cancer Res. 2006 Nov 1;12(21):6359-66
pubmed: 17085646
J Biol Chem. 2003 May 2;278(18):15641-51
pubmed: 12594228
PLoS One. 2011;6(10):e26177
pubmed: 22046260
Endocrinology. 2011 Jul;152(7):2546-51
pubmed: 21540285
CA Cancer J Clin. 2019 Nov;69(6):438-451
pubmed: 31577379
Nature. 2015 Nov 19;527(7578):329-35
pubmed: 26524530
Mol Cell Biol. 2003 Mar;23(6):1994-2008
pubmed: 12612073
Cell Commun Signal. 2011 May 02;9(1):10
pubmed: 21535875
Clin Cancer Res. 2009 Jan 1;15(1):226-37
pubmed: 19118050
Vitam Horm. 2009;80:667-97
pubmed: 19251055
Oncotarget. 2016 Aug 16;7(33):52710-52728
pubmed: 27384677
Oncoimmunology. 2017 Jan 23;6(1):e1263412
pubmed: 28197390
Nat Commun. 2015 Oct 14;6:8499
pubmed: 26465273
J Biol Chem. 2001 Jul 20;276(29):27071-6
pubmed: 11369763
Oncotarget. 2017 Oct 10;8(55):94393-94406
pubmed: 29212236
Cancer Treat Rev. 2014 Aug;40(7):862-71
pubmed: 24774538
Nat Commun. 2019 Nov 1;10(1):5016
pubmed: 31676788
Breast Cancer Res. 2015 May 21;17:69
pubmed: 25990368
Annu Rev Med. 2011;62:233-47
pubmed: 20887199
Biomark Res. 2017 May 12;5:19
pubmed: 28507762
Cancer Res. 2014 Dec 1;74(23):6806-19
pubmed: 25252914
Breast Cancer Res Treat. 2008 Apr;108(3):351-61
pubmed: 17592774
J Clin Endocrinol Metab. 2011 Mar;96(3):766-74
pubmed: 21123448
Cancer Res. 2005 Jun 15;65(12):5278-83
pubmed: 15958574
Breast Cancer Res. 2017 Apr 11;19(1):46
pubmed: 28399903
J Biol Chem. 1994 Jun 10;269(23):16433-42
pubmed: 8206951
Endocr Relat Cancer. 2014 Mar 07;21(2):355-69
pubmed: 24481325
Oncogene. 2018 Apr;37(15):2022-2036
pubmed: 29367764
Histol Histopathol. 2018 Feb;33(2):133-145
pubmed: 28681373
Pharmacol Rev. 2015 Jul;67(3):505-40
pubmed: 26023144
Sci Rep. 2018 Jun 11;8(1):8859
pubmed: 29891854
NPJ Breast Cancer. 2016;2:
pubmed: 26998515
Nature. 2008 Aug 7;454(7205):776-9
pubmed: 18594509
J Transl Med. 2015 Feb 15;13:64
pubmed: 25885919
Oncogene. 2014 Mar 20;33(12):1485-94
pubmed: 23584474
Breast Cancer Res. 2013;15(5):R102
pubmed: 24176089
Endocrinology. 2019 Feb 1;160(2):430-446
pubmed: 30597041
Int J Biochem Cell Biol. 2014 Jan;46:56-67
pubmed: 24275097
Cells. 2020 Mar 04;9(3):
pubmed: 32143514
Int J Cancer. 2020 Mar 15;146(6):1674-1685
pubmed: 31340060
J Oncol. 2012;2012:635614
pubmed: 22927847
J Biol Chem. 2003 Jan 24;278(4):2701-12
pubmed: 12421825
Sci Rep. 2016 Apr 13;6:24354
pubmed: 27072893
Int J Mol Sci. 2018 Jul 10;19(7):
pubmed: 29996493
Biochem Biophys Res Commun. 1984 Oct 15;124(1):203-9
pubmed: 6093785
Oncotarget. 2016 Feb 16;7(7):7683-700
pubmed: 26655502
EMBO J. 2009 Mar 4;28(5):523-32
pubmed: 19153601
Front Oncol. 2015 Oct 15;5:230
pubmed: 26528439
Cancer Res. 2009 Feb 15;69(4):1302-13
pubmed: 19190339
EMBO J. 2001 Nov 1;20(21):6050-9
pubmed: 11689445
Mol Carcinog. 2017 Feb;56(2):580-593
pubmed: 27341075
Breast Cancer Res. 2013;15(4):R64
pubmed: 23947803
Mol Oncol. 2017 Sep;11(9):1241-1262
pubmed: 28618162
Science. 2002 May 31;296(5573):1642-4
pubmed: 12040178
Recent Results Cancer Res. 2007;174:151-67
pubmed: 17302193
Clin Dev Immunol. 2012;2012:948098
pubmed: 22778768
Breast Cancer Res Treat. 2017 Nov;166(1):95-107
pubmed: 28730338
Steroids. 2016 Oct;114:48-58
pubmed: 27641443
Chin Med J (Engl). 2009 Nov 20;122(22):2763-9
pubmed: 19951611
Cancer Res. 2010 Jul 15;70(14):6036-46
pubmed: 20551055
Int J Cancer. 2019 Nov 15;145(10):2827-2839
pubmed: 31381136
Prog Lipid Res. 2018 Jan;69:11-20
pubmed: 29175445
Semin Oncol. 2004 Feb;31(1 Suppl 3):28-38
pubmed: 15052541
Int J Oncol. 2013 Jul;43(1):5-12
pubmed: 23673510
Clin Exp Metastasis. 2008;25(4):401-10
pubmed: 18307047
Endocr Relat Cancer. 2014 Oct;21(5):739-53
pubmed: 25012984
Trends Endocrinol Metab. 2009 Dec;20(10):477-82
pubmed: 19783454
Proc Natl Acad Sci U S A. 1999 Sep 28;96(20):11217-22
pubmed: 10500157
Nat Rev Cancer. 2016 Aug 23;16(9):582-98
pubmed: 27550820
Cell. 2013 Aug 29;154(5):1060-1073
pubmed: 23993096
Mol Cancer Res. 2014 Nov;12(11):1644-1654
pubmed: 25030371
Cancer Res. 2018 Sep 15;78(18):5243-5258
pubmed: 30012670
Oncogene. 2010 Apr 8;29(14):2083-92
pubmed: 20101226
Nat Rev Genet. 2007 May;8(5):341-52
pubmed: 17440531
Mol Cell Endocrinol. 2013 Aug 25;376(1-2):23-32
pubmed: 23748028
Mutat Res Rev Mutat Res. 2017 Apr - Jun;772:78-104
pubmed: 28528692
J Mol Histol. 2015 Oct;46(4-5):365-75
pubmed: 26208571
J Transl Med. 2020 Jan 3;18(1):1
pubmed: 31900168
Steroids. 2008 Oct;73(9-10):880-4
pubmed: 18342899
Oncogene. 2013 Feb 7;32(6):678-88
pubmed: 22430216
Cancer Res. 2004 Jan 1;64(1):236-42
pubmed: 14729630
Diabetologia. 2020 Jan;63(1):75-84
pubmed: 31511931
J Clin Endocrinol Metab. 2002 Jan;87(1):245-54
pubmed: 11788654
Lancet Oncol. 2013 Mar;14(3):228-35
pubmed: 23414585
Mol Cell. 2006 Nov 3;24(3):367-81
pubmed: 17081988
Oncotarget. 2018 May 25;9(40):25946-25956
pubmed: 29899833
J Cancer Res Clin Oncol. 2011 Jun;137(6):975-83
pubmed: 21132511
Nature. 2016 Dec 22;540(7634):552-558
pubmed: 27974799
PLoS One. 2008 May 21;3(5):e2238
pubmed: 18493596
Expert Opin Ther Targets. 2020 Jun;24(6):559-572
pubmed: 32249708
Front Endocrinol (Lausanne). 2015 Apr 24;6:59
pubmed: 25964777
J Mol Endocrinol. 2018 Jul;61(1):T61-T68
pubmed: 29378771
Breast Cancer Res. 2017 Dec 6;19(1):129
pubmed: 29212519
Proc Natl Acad Sci U S A. 2009 Aug 25;106(34):14287-92
pubmed: 19706513
Breast Cancer Res Treat. 2011 Aug;128(3):703-711
pubmed: 20842526
Cancer J. 2015 Jul-Aug;21(4):267-73
pubmed: 26222078
Med Res Rev. 2015 Jan;35(1):1-62
pubmed: 24827545
Cancer Res. 2014 Aug 1;74(15):4053-64
pubmed: 24894716
Biochim Biophys Acta Mol Cell Res. 2019 Nov;1866(11):118522
pubmed: 31394114
Mol Cell Biol. 1999 May;19(5):3278-88
pubmed: 10207053
J Clin Endocrinol Metab. 2014 Feb;99(2):E217-25
pubmed: 24297795
Sci Rep. 2017 Jun 20;7(1):3917
pubmed: 28634395
Proc Natl Acad Sci U S A. 2010 Dec 14;107(50):21677-82
pubmed: 21098274
Oncotarget. 2017 Apr 25;8(17):29501-29518
pubmed: 28427155
Cancer Res. 2012 Jul 1;72(13):3372-80
pubmed: 22573715
Trends Mol Med. 2012 Sep;18(9):534-43
pubmed: 22921864
Matrix Biol. 2014 Apr;35:82-90
pubmed: 24389353
EMBO J. 1996 Mar 15;15(6):1292-300
pubmed: 8635462
Acta Biomater. 2017 Jan 1;47:14-24
pubmed: 27662809
Cell. 2016 Jun 30;166(1):47-62
pubmed: 27368100
Nat Rev Cancer. 2011 Jun;11(6):411-25
pubmed: 21593787
Cancer Res. 2008 Dec 1;68(23):9712-22
pubmed: 19047149
N Engl J Med. 2006 Jan 19;354(3):270-82
pubmed: 16421368
Cell Metab. 2015 Oct 6;22(4):577-89
pubmed: 26365179
Oncogene. 2012 Apr 5;31(14):1825-34
pubmed: 21860415
Clin Cancer Res. 2006 Dec 1;12(23):6865-8
pubmed: 17145802
BMC Cancer. 2016 Sep 08;16(1):724
pubmed: 27609180
Cancer Epidemiol Biomarkers Prev. 2008 Jul;17(7):1719-22
pubmed: 18628423
J Clin Med. 2014 Dec 22;3(4):1561-74
pubmed: 26237614
Nat Rev Cancer. 2015 May;15(5):261-75
pubmed: 25907219
Nat Cell Biol. 2001 Jan;3(1):15-23
pubmed: 11146621
J Natl Cancer Inst. 2012 Jul 3;104(13):975-81
pubmed: 22761272
Immunity. 2014 Nov 20;41(5):815-29
pubmed: 25453823
Cancer Res. 2016 Nov 1;76(21):6205-6217
pubmed: 27503928
Front Endocrinol (Lausanne). 2015 Mar 06;6:30
pubmed: 25798130
J Steroid Biochem Mol Biol. 2013 Sep;137:50-6
pubmed: 23542661
Cancer. 2020 May 15;126 Suppl 10:2365-2378
pubmed: 32348571
Sci Rep. 2017 Apr 7;7(1):732
pubmed: 28389653
Front Endocrinol (Lausanne). 2014 May 06;5:66
pubmed: 24834064
Nat Rev Cancer. 2009 Apr;9(4):265-73
pubmed: 19262571
Front Cell Dev Biol. 2018 May 08;6:48
pubmed: 29868579
Mol Endocrinol. 1995 Apr;9(4):443-56
pubmed: 7659088
J Cell Biol. 2007 Jan 1;176(1):19-26
pubmed: 17190790
J Cell Biochem. 2006 May 15;98(2):440-50
pubmed: 16440325
Proc Natl Acad Sci U S A. 2005 Oct 25;102(43):15593-8
pubmed: 16230630
Nucleic Acids Res. 2014 Feb;42(3):1893-903
pubmed: 24185704
Ann Oncol. 2013 Oct;24 Suppl 6:vi7-23
pubmed: 23970019
Int J Cancer. 2017 Jun 15;140(12):2657-2666
pubmed: 28268252
Mol Endocrinol. 2002 Jan;16(1):100-15
pubmed: 11773442
Front Endocrinol (Lausanne). 2014 Feb 04;5:10
pubmed: 24550888
J Mammary Gland Biol Neoplasia. 2015 Jun;20(1-2):39-50
pubmed: 26265122
Adipocyte. 2013 Jul 1;2(3):165-9
pubmed: 23991363
Mol Cell Endocrinol. 2012 Jun 24;357(1-2):71-9
pubmed: 21945473
Cancer Res. 2015 Jan 15;75(2):284-95
pubmed: 25488750
Proc Natl Acad Sci U S A. 2012 Aug 21;109(34):13515-20
pubmed: 22869695
Trends Cancer. 2016 Dec;2(12):758-770
pubmed: 28741521
Clin Cancer Res. 2014 Jun 15;20(12):3071-7
pubmed: 24677373
Science. 2005 Mar 11;307(5715):1625-30
pubmed: 15705806
Invest New Drugs. 2015 Feb;33(1):194-200
pubmed: 25342141
Int J Mol Sci. 2019 Jul 02;20(13):
pubmed: 31269742
Adv Anat Pathol. 2017 Mar;24(2):78-81
pubmed: 28098572
Nature. 2015 Jul 16;523(7560):313-7
pubmed: 26153859
Mol Cell Endocrinol. 2015 Nov 5;415:32-44
pubmed: 26257240